|
Omalizumab para el tratamiento del asma [Omalizumab for the management of asthma] |
Ruano Gándara R, Rey-Ares L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ruano Gándara R, Rey-Ares L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A. Omalizumab para el tratamiento del asma. [Omalizumab for the management of asthma] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rapida No. 440. 2015 Authors' objectives To assess the available evidence on the efficacy, safety and coverage related aspects regarding omalizumab in the management of asthma.
Asthma is a chronic inflammatory disease of the lung with upper airway hyperreactivity. In Argentina, its prevalence is 5.98%. Eighty percent of the patients present allergic asthma.
The symptoms include wheezing, shortness of breath and cough secondary to bronchoconstriction and increased mucus production. It is diagnosed by means of history taking, physical examination and positive response to short-acting beta-agonists during a spriometry.
Omalizumab is proposed as the last step in the management of persistent allergic asthma.
Omalizumab is a recombinant humanized monoclonal antibody, which binds to free IgE, thus preventing its interaction with effector cells. Authors' conclusions Evidence of moderate methodological quality shows that the use of omalizumab in persistent, moderate to severe allergic asthma may potentially reduce the number of exacerbations, the use of oral corticoids and patient symptoms. The information in children is not enough; there are no studies beyond one-year follow-up.
Furthermore, no studies comparing omalizumab with active treatments have been found.
There is consensus about its use in the surveyed clinical practice guidelines and coverage policies, especially in individuals over 12 years old with persistent IgE-mediated allergic asthma, who are frequently or continuously using corticoids.
Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Anti-Idiotypic; Antibodies, Monoclonal, Humanized; Asthma; Disease Management; Humans Language Published Spanish Country of organisation Argentina English summary An English language summary is available. Address for correspondence Institute for Clinical Effectiveness and Health Policy, Viamonte 2146 - 3 Piso, C1056ABH Ciudad de Buenos Aires, Argentina Tel: +54 11 49 66 00 82 Fax:+54 11 49 53 40 58 Email: info@iecs.org.ar AccessionNumber 32015001170 Date abstract record published 17/11/2015 |
|
|
|